Gastrointestinal effects: the main titration bottleneck Nausea, diarrhea, constipation, and vomiting run around 40 to 44% overall, dose-dependent in how many people report them but mild-dominant in severity: severe events stay at or below about 1.7% in any category even at the top dose. In the obesity program the by-dose rates run nausea 25/29/28%, diarrhea 19/21/23%, and vomiting 8/11/13% at 5/10/15 mg. They concentrate during escalation and ease with time on a held dose
Semaglutide reduced major adverse cardiovascular events by 20 percent
Not for individuals with cardiovascular conditions, high blood pressure, or any heart condition
Our team advises against pre-filling syringes for long-term storage
It is entirely possible retatrutide will have the same side effects as other GLP1s, which are rare but serious
As a result, health insurance companies do not cover this procedure